Pediatric PPI Use and Fractures

Nathan R. Fleishman  
*Children's Mercy Hospital*, nrfleishman@cmh.edu

Troy Richardson  
*Children's Mercy Hospital*, trichardson@cmh.edu

Thomas M. Attard  
*Children's Mercy Hospital*, tmattard@cmh.edu

Follow this and additional works at: [https://scholarlyexchange.childrensmercy.org/posters](https://scholarlyexchange.childrensmercy.org/posters)

Part of the Gastroenterology Commons, Pediatrics Commons, and the Pharmaceutical Preparations Commons

Recommended Citation

Fleishman, Nathan R.; Richardson, Troy; and Attard, Thomas M., "Pediatric PPI Use and Fractures" (2019). *Posters*. 100.  
[https://scholarlyexchange.childrensmercy.org/posters/100](https://scholarlyexchange.childrensmercy.org/posters/100)

This Book is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact bpfannenstiel@cmh.edu.
**Pediatric PPI Use and Fractures**

Nathan Fleishman, MD\(^1\); Troy Richardson PhD \(^2\); Thomas M. Attard, MD\(^1\);

\(^1\) Children's Mercy Kansas City, Dept of Pediatric Gastroenterology; \(^2\) Children's Hospital Association

**BACKGROUND**

- Proton pump inhibitors (PPI) are one of the most widely prescribed classes of medications
- Increasing reports of safety concerns regarding PPI use including the risk of fracture
- Limited studies examining risk among pediatric patients

**STUDY AIMS**

- Compare rate of fracture among pediatric patients exposed to PPI to rate among patients without exposure
- Determine if fracture location differs among children exposed to PPI

**METHODS**

- Retrospective propensity-matched analysis using Pediatric Health Information Systems database
- Initial encounters for patients 6 months to 15.5 years between 06/01/2011 to 12/31/2015
- Patients evaluated over 2-year period for encounter resulting from fracture
- Extensive exclusion criteria of conditions and medications which could increase the risk of fracture were applied

**FINDINGS**

- 32,001 encounters with documented PPI use were propensity matched to the same number of encounters with no PPI documented
- Statistically significant higher rate of fractures among the PPI exposed group (1.4% vs 1.2%, \(p = 0.019\))
- Adjusting for remaining differences in sex, race, encounter type, payer, and resource intensity after matching, this remained statistically significant \((p = 0.017\) OR (95% CI) of 1.2 (1.0,1.4))
- PPI cohort more likely to suffer from lower extremity, rib, and spinal fractures \((p = 0.01)\)
- No relationship between fracture risk and individual PPIs \((p = 0.205)\)

**CONCLUSIONS**

- There may be an increased risk of fracture among otherwise healthy pediatric patients taking PPI
- Serious consideration of fracture risk should be considered prior to prescribing PPI to pediatric patients
- Future studies examining mechanism of PPI effects on bone health are needed

**RESOURCES**

- Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. *Calcif Tissue Int.* 2006;79(2):76-83

**CONTACT INFORMATION**

- nrfleishman@cmh.edu